Check-Cap Ltd. (NASDAQ:CHEK) Short Interest Update

Check-Cap Ltd. (NASDAQ:CHEK) was the recipient of a significant drop in short interest in the month of October. As of October 15th, there was short interest totaling 290,800 shares, a drop of 38.6% from the September 30th total of 473,700 shares. Approximately 5.5% of the shares of the company are short sold. Based on an average daily volume of 2,910,000 shares, the days-to-cover ratio is currently 0.1 days. Based on an average daily volume of 2,910,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 5.5% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Check-Cap in a research report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Check-Cap Trading Down 0.4%

Shares of Check-Cap stock traded down $0.01 on Monday, reaching $1.38. The stock had a trading volume of 30,317 shares, compared to its average volume of 1,128,714. Check-Cap has a 1 year low of $0.56 and a 1 year high of $3.13. The company has a market cap of $8.10 million, a P/E ratio of -0.50 and a beta of 0.50. The business’s 50 day moving average is $1.59 and its two-hundred day moving average is $1.06.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.